Clinical Trial Update: An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients. [Phase 3]

View source ↗

Summary

A Phase 3 open study assessing the safety and efficacy of Optivate in patients with severe Haemophilia A has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• Optivate (von Willebrand factor concentrate (plasma-derived))

Snippet

Sponsor: Bio Products Laboratory | Conditions: Haemophilia A | Phase 3 | Status: COMPLETED